MDWD - MediWound advances late-stage study of NexoBrid in pediatric burn patients

MediWound (MDWD) announces the completion of enrollment in a Phase 3 clinical trial evaluating NexoBrid in 145 patients younger than 18 years old with severe burns.The study will compare NexoBrid (concentrate of proteolytic enzymes enriched in Bromelain), a topically administered biologic that enzymatically removes nonviable burn tissue (eschar), to standard-of-care treatment. Patients will be followed for 24 months (includes a month 12 timepoint).The primary endpoint is earlier eschar removal. The aim is to demonstrate the superiority of NexoBrid for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time.Topline 12-month data should be available in H2 2021.

For further details see:

MediWound advances late-stage study of NexoBrid in pediatric burn patients